Resources from the same session
2800 - Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
Presenter: Jaume Capdevila Castillon
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
5468 - Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer
Presenter: Sophie Leboulleux
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
3442 - Activity & Safety of Spartalizumab (PDR001) in Patients (pts) With Advanced Neuroendocrine Tumors (NET) of Pancreatic (Pan), Gastrointestinal (GI), or Thoracic (T) Origin, & Gastroenteropancreatic Neuroendocrine Carcinoma (GEP NEC) Who Have Progressed on Prior Treatment (Tx)
Presenter: James Yao
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Abstract
2346 - Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial
Presenter: Panpan Zhang
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Proffered paper session - NETs and endocrine tumours - Invited Discussant 1307O
Presenter: Eric Baudin
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Slides
Webcast
Proffered paper session - NETs and endocrine tumours - Invited Discussant 1819O
Presenter: Christine Spitzweg
Session: Proffered paper session - NETs and endocrine tumours
Resources:
Slides
Webcast